Program
clazakizumab
Also written as “BMS-945429”, “ALD518” and “Clazakizumab”.
Its studies are mostly in Arthritis, Rheumatoid · Atherosclerosis · Crohn Disease · Arthritis, Psoriatic · Stomatitis, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| CSL | 90 open or running | phase 3since Nov 6, 2018 | Mar 20, 2009 | none ahead |
| Eli Lilly | 11 open or running | phase 2since Aug 21, 2026 | Aug 21, 2026 | May 2027phase 2 · NCT07783802 |
- Named in Eli Lilly’s own pipeline as
Clazakizumab
, phase 2, as of Oct 29, 2026 (source).
Also a collaborator on its studies: icon-clinical-research.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 20, 2009First studies: 2 phase 2 studiesNew to CSLCSL · NCT00867516, NCT00866970
- Jun 13, 2011Phase 2 study in Arthritis, RheumatoidCSL · NCT01373151 · 418 enrolled · United States, Argentina, Belgium and more
- Jul 25, 2011Phase 2 study in StomatitisCSL · NCT01403064 · 76 enrolled · United States, Australia, Austria and more
- Nov 14, 2011Phase 2 study in Arthritis, PsoriaticCSL · NCT01490450 · 165 enrolled · United States, Argentina, Australia and more
- Feb 6, 2012Phase 2 study in Acute GvHDCSL · NCT01530256 · 3 enrolled · United States
- Mar 1, 2012Phase 2 study in Crohn DiseaseCSL · NCT01545050 · 72 enrolled · United States, Austria, Canada and more
- Dec 6, 2013Phase 2 study in Arthritis, RheumatoidCSL · NCT02015520 · 143 enrolled · United States, Argentina, Canada and more
- Nov 6, 2018Phase 3 study in Antibody-mediated RejectionCSL · NCT03744910 · 194 enrolled · United States, Australia, Austria and more
- Aug 21, 2026Eli Lilly's first study: phase 2 study in AtherosclerosisNew to Eli LillyEli Lilly · NCT07783802 · 120 planned · United States, Argentina, Japan and more
Ahead
- May 2027Primary completion: phase 2 study in AtherosclerosisEli Lilly · NCT07783802
TargetBeta
“A humanized monoclonal antibody directed against the pro-inflammatory cytokine interleukin-6 (Il-6) with potential immunomodulating activity. Upon administration, clazakizumab binds to and blocks the activity of IL-6, which may mitigate the catabolic effects of IL-6.”NCIt, read by Claude
“Interleukin-6 inhibitor”ChEMBL 37, by rule
Other programs on IL6
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| olokizumabrule | R-Pharm | phase 3 | 19 |
| ziltivekimabrule | Novo Nordisk | phase 3 | 12 |
| pacibekitugrule | Novartis | phase 3 | 1 |
| isomyosaminerule | tnf-pharmaceuticals-inc | phase 2 | 1 |
Studies
All 10 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07783802Atherosclerosis · United States, Argentina, Japan and more | 2 | Recruiting | Eli Lilly | May 2027 | 120 |
| NCT03744910Antibody-mediated Rejection · United States, Australia, Austria and more | 3 | Terminated | CSL | Apr 8, 2024 | 194 |
| NCT02015520Arthritis, Rheumatoid · United States, Argentina, Canada and more | 2 | Completed | CSL | Jun 2013 | 143 |
| NCT01545050Crohn Disease · United States, Austria, Canada and more | 2 | Terminated | CSL | Dec 2013 | 72 |
| NCT01530256Acute GvHD · United States | 2 | Terminated | CSL | Mar 2013 | 3 |
| NCT01490450Arthritis, Psoriatic · United States, Argentina, Australia and more | 2 | Completed | CSL | Jun 2013 | 165 |
| NCT01403064Stomatitis · United States, Australia, Austria and more | 2 | Terminated | CSL | Apr 2013 | 76 |
| NCT01373151Arthritis, Rheumatoid · United States, Argentina, Belgium and more | 2 | Completed | CSL | Sep 2012 | 418 |
| NCT00867516Arthritis, Rheumatoid · Canada, Georgia, India and more | 2 | Completed | CSL | Jun 2009 | 127 |
| NCT00866970Fatigue · Australia, Canada, Georgia and more | 2 | Completed | CSL | Aug 2009 | 124 |
How it is read
Names in the registry
- “BMS-945429”, 16 entries
- “ALD518”, 8 entries
- “Clazakizumab”, 3 entries
Conditions, from the studies’ own filings
- Arthritis, Rheumatoid, 3 studies
- Atherosclerosis, 1 study
- Crohn Disease, 1 study
- Arthritis, Psoriatic, 1 study
- Stomatitis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.